Related Experiment Video

Updated: Jul 30, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after

Akiko Koizumi1, Yukiho Tamura1, Ryohei Yoshida2

  • 1Medicine, Asahikawa Medical University School of Medicine, Asahikawa, JPN.

Cureus
|May 18, 2023
PubMed

Insights

Immune checkpoint inhibitors show promise for patients with advanced SMARCA4-deficient non-small cell lung cancer (NSCLC) and poor performance status. Two cases demonstrated significant tumor regression and improved patient condition after ICI treatment.

Area of Science:

  • Oncology
  • Genetics
  • Immunotherapy

Background:

  • SMARCA4 mutations are common in non-small cell lung cancer (NSCLC) and linked to poor prognosis.
  • Limited data exists on immune checkpoint inhibitor (ICI) efficacy in SMARCA4-deficient NSCLC with poor performance status (PS).

Observation:

  • This report details two cases of advanced NSCLC with SMARCA4 deficiency.
  • These patients had poor performance status and received treatment with ICIs.
  • Both patients experienced significant tumor regression and improved general condition.

Findings:

  • Immune checkpoint inhibitors demonstrated notable efficacy in advanced SMARCA4-deficient NSCLC.
  • Treatment led to marked tumor regression in patients with poor performance status.
  • Patients showed significant improvement in their overall health and condition.

Implications:

  • ICIs may represent a viable therapeutic option for advanced SMARCA4-deficient NSCLC, including those with poor PS.
  • These findings warrant further investigation into ICI efficacy in this specific NSCLC subtype.
  • Successful treatment outcomes suggest potential for improved survival and quality of life in this patient population.
Keywords:
brg1immune checkpoint inhibitornon-small cell lung cancerperformance statussmarca4-deficient

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
584
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K